Literature DB >> 19039775

Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3.

Sarah E Allan1, George X Song-Zhao, Thomas Abraham, Alicia N McMurchy, Megan K Levings.   

Abstract

FOXP3 is required for the development of Treg and its expression is often used as a surrogate marker of functional suppression. However, it is now known that activated human T effector cells can also express FOXP3 without acquiring regulatory activity. To more closely examine the requirements for FOXP3 to reprogram human T cells into Treg, we developed a conditionally active form of FOXP3 and show here that full acquisition of Treg phenotype and function is strictly dependent on the amount of active FOXP3 a T cell expresses. In addition, the phenotypic and functional alterations induced by FOXP3 are only fully manifested following prolonged induction of protein activity. Induction of FOXP3 activity does not upregulate EBI3 or p35 mRNA, providing evidence that secretion of IL-35 does not substantially contribute to the suppressive mechanism of human Treg. These data represent the first formal evidence that FOXP3 acts as a quantitative regulator rather than a simple molecular switch for Treg.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19039775     DOI: 10.1002/eji.200838373

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  39 in total

Review 1.  Foxp3+ regulatory T cells: differentiation, specification, subphenotypes.

Authors:  Markus Feuerer; Jonathan A Hill; Diane Mathis; Christophe Benoist
Journal:  Nat Immunol       Date:  2009-07       Impact factor: 25.606

Review 2.  Interleukin-35: Expanding Its Job Profile.

Authors:  Deepali V Sawant; Kristia Hamilton; Dario A A Vignali
Journal:  J Interferon Cytokine Res       Date:  2015-04-28       Impact factor: 2.607

Review 3.  Methods to manufacture regulatory T cells for cell therapy.

Authors:  K N MacDonald; J M Piret; M K Levings
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

4.  Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance.

Authors:  Vandana Chaturvedi; Lauren W Collison; Clifford S Guy; Creg J Workman; Dario A A Vignali
Journal:  J Immunol       Date:  2011-05-16       Impact factor: 5.422

Review 5.  Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer.

Authors:  Harald von Boehmer; Carolin Daniel
Journal:  Nat Rev Drug Discov       Date:  2013-01       Impact factor: 84.694

Review 6.  Human regulatory T cells in autoimmune diseases.

Authors:  Gregory L Cvetanovich; David A Hafler
Journal:  Curr Opin Immunol       Date:  2010-09-24       Impact factor: 7.486

7.  Levels of interleukin-35 and its relationship with regulatory T-cells in chronic hepatitis B patients.

Authors:  Yin-yue Shi; Ming-jia Dai; Gui-ping Wu; Pei-pei Zhou; Yuan Fang; Xue-bing Yan
Journal:  Viral Immunol       Date:  2014-12-10       Impact factor: 2.257

8.  Foxp3 and Toll-like receptor signaling balance Treg cell anabolic metabolism for suppression.

Authors:  Valerie A Gerriets; Rigel J Kishton; Marc O Johnson; Sivan Cohen; Peter J Siska; Amanda G Nichols; Marc O Warmoes; Aguirre A de Cubas; Nancie J MacIver; Jason W Locasale; Laurence A Turka; Andrew D Wells; Jeffrey C Rathmell
Journal:  Nat Immunol       Date:  2016-10-03       Impact factor: 25.606

9.  Autoimmunity: increasing suspects in the CD4+ T cell lineup.

Authors:  Matthew T Palmer; Casey T Weaver
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

10.  The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.

Authors:  Liguo Yin; Yongpeng Ge; Hanbo Yang; Qinglin Peng; Xin Lu; Yamei Zhang; Guochun Wang
Journal:  Clin Rheumatol       Date:  2016-08-08       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.